目的:探讨定量n 99Tcn m-联肼尼克酰胺(HYNIC)-前列腺特异膜抗原(PSMA) SPECT/CT显像在前列腺癌诊断中的价值。n 方法:回顾性分析2018年11月至2021年3月间河南省人民医院临床疑诊前列腺癌的56例患者[年龄(69.8±8.0)岁]资料，所有患者的n 99Tcn m-HYNIC-PSMA SPECT/CT显像均示前列腺放射性摄取增高。依据病理结果将患者分为前列腺癌组(n n＝45)和非前列腺癌组(n n＝11)。应用xSPECT-QUANT软件对前列腺高摄取区进行定量分析，测SUVn max。采用两独立样本n t检验、Mann-Whitney n U检验、ROC曲线及Spearman相关分析处理数据。n 结果:前列腺癌组的SUVn max高于非前列腺癌组(10.79±5.96和3.60±1.27；n t＝7.43，n P<0.001)；当SUVn max≥6.46时，AUC为0.887，诊断前列腺癌的灵敏度为73.3%(33/45)，特异性为11/11，阳性预测值为100%(33/33)，阴性预测值为47.8%(11/23)，准确性为78.6%(44/56)。前列腺癌SUVn max与Gleason评分呈正相关(n rs＝0.632，n P<0.001)。Gleason评分≥8分的患者(n n＝29)较Gleason评分≤7分者(n n＝16)的SUVn max高(n z＝-3.89，n P<0.001)；Gleason评分≤7分者与非前列腺癌患者PSA水平差异无统计学意义(n z＝-1.63，n P＝0.110)，但SUVn max差异有统计学意义(n z＝-2.22，n P＝0.026)。有转移者(n n＝23)SUVn max高于无转移者(n n＝22；12.99±5.85和8.50±5.28；n t＝2.69，n P＝0.010)；当SUVn max≥13.02时，ROC AUC为0.709，诊断前列腺癌转移的灵敏度为56.5%(13/23)，特异性为86.4%(19/22)，准确性为71.1%(32/45)。n 结论:定量n 99Tcn m-HYNIC-PSMA SPECT/CT显像在前列腺癌患者中可行，SUVn max在诊断前列腺癌、评估恶性程度及预测转移方面有一定价值。n “,”Objective:To explore the diagnostic value of quantitative n 99Tcn m-hydrazinonicotinamide(HYNIC)-prostate specific membrane antigen (PSMA) SPECT/CT in patients with prostate cancer.n Methods:From November 2018 to March 2021, the data of 56 patients ((69.8±8.0) years) with clinically suspected prostate cancer, who had elevated radioactive uptake in prostate on n 99Tcn m-HYNIC-PSMA SPECT/CT images in Henan Provincial People′s Hospital, were retrospectively analyzed. According to the pathological results, patients were divided into prostate cancer group (n n=45) and non-prostate cancer group (n n=11). The xSPECT-QUANT software was used to quantitatively analyze the high uptake area of the prostate, and SUVn max was measured. The independent-sample n t test, Mann-Whitney n U test, ROC curve and Spearman correlation analysis were used for data analysis.n Results:The prostate cancer group had higher SUVn max than non-prostate cancer group (10.79±5.96 n vs 3.60±1.27; n t=7.43, n P<0.001). When SUVn max≥6.46, the AUC of prostate cancer was 0.887, with the diagnostic sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 73.3%(33/45), 11/11, 100%(33/33), 47.8%(11/23), 78.6%(44/56), respectively. The SUVn max of prostate cancer group was positively correlated with Gleason score (n rs=0.632, n P<0.001). The SUVn max of 29 patients with Gleason score≥8 was higher than that of 16 patients with Gleason score≤7 (n z=-3.89, n P<0.001). There was no statistical difference in PSA level between patients with Gleason score≤ 7 and patients with non-prostate cancer (n z=-1.63, n P=0.110), but the SUVn max was significantly different (n z=-2.22, n P=0.026). The SUVn max of 23 patients with metastases was higher than that of 22 patients without metastasis (12.99±5.85 n vs 8.50±5.28; n t=2.69, n P=0.010). ROC analysis showed that the AUC was 0.709; with SUVn max≥13.02 as the threshold, the sensitivity for diagnosing prostate cancer metastases was 56.5%(13/23), the specificity was 86.4%(19/22), and the accuracy was 71.1%(32/45).n Conclusions:The n 99Tcn m-HYNIC-PSMA SPECT/CT quantitative analysis is feasible in patients with prostate cancer. SUVn max of n 99Tcn m-HYNIC-PSMA can be used in the diagnosis of prostate cancer, assessment of the malignancy and prediction of metastasis.n